Renowned Urologic Oncologist, Dr. Stuart Holden, Joins UCLA Urology
Article ID: 617529
Released: 6-May-2014 3:00 PM EDT
Source Newsroom: University of California, Los Angeles (UCLA), Health Sciences
Newswise — Dr. Stuart Holden has joined the UCLA faculty as a health sciences clinical professor in the Department of Urology at the David Geffen School of Medicine at UCLA and associate director of the UCLA Institute of Urologic Oncology.
The internationally respected urologic oncologist and surgeon has worked on the frontlines of prostate cancer for more than 36 years while pioneering new treatments for urologic cancers.
With his expertise in treating urologic cancers, Dr. Holden will be working closely with Dr. Arie Belldegrun, professor of urology and director of the Institute of Urologic Oncology and will establish an executive urology program at UCLA.
Holden is recognized as an expert in prostate cancer research throughout the medical community. His dedication to patient care led to him being named medical director of the Prostate Cancer Foundation, the largest prostate cancer research funding organization in the world, which was founded by Michael Milken. He has held this position since the foundation’s inception in 1993.
“We are thrilled to have recruited Dr. Holden to join UCLA Urology,” said Dr. Mark S. Litwin, professor and chair of the UCLA Department of Urology. “For more than 50 years, our mission has been to deliver compassionate, high-quality patient care through innovative research and specialized urologic programs. It is an honor to have Dr. Holden fortify our team with his extensive urologic oncology expertise as we continue to improve urologic health care and work to heal humankind, one patient at a time.”
Holden introduced radioactive seed implantation to Los Angeles and was an early adopter of ultrasound-guided prostate biopsy. He has seen his career-long advocacy of active surveillance - in which cancers are closely monitored with blood and other tests - become an established treatment option. At the Prostate Cancer Foundation, he has overseen funding for prostate cancer research collaborations become multi-disciplinary, inter-institutional and nowglobal.
Prior to joining UCLA, Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. He was a founding partner at Tower Urology in Los Angeles.
“UCLA urology has afforded me the opportunity to take on new challenges in my career,” said Dr. Holden. “UCLA urology’s commitment to outstanding patient care and research in a collaborative environment at the Clark Urology Center and UCLA Institute of Urologic Oncology is well known throughout the world.”
“I am looking forward to integrating oncology care with a multidisciplinary focus to help create groundbreaking results for the patients here at UCLA and beyond. In addition, I will have the privilege of joining with world-class colleagues as we teach and train future leaders in urologic oncology. This was an opportunity I just could not pass up.”
Holden completed his medical degree, and surgical training at New York Hospital Cornell University Medical College. He completed his urology residency at Emory University and fellowships in urology and developmental genetics at Memorial-Sloan Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society.
About UCLA Urology:The Department of Urology at UCLA boasts a team of renowned physicians, surgeons, and researchers. The internationally respected program has been recognized as the “Best in the West” and ranks fourth in the nation by U.S. News and World Reports. For more than 50 years, the multidisciplinary team has been the benchmark for urology care worldwide with its dedication to urologic health. From cutting edge prostate, bladder and testicular cancer treatments, to life changing kidney and urinary incontinence care, UCLA’s urologists are pioneering health solutions for patients everyday.